

Symptom relief or pain reduction with *Phyllanthus niruri* (Chanca Piedra)

The following studies observed the effect of *P. niruri* on symptoms of urinary stones.

Phyllanthus niruri and Chrysanthellum americanum in association with potassium and magnesium citrates are able to prevent symptomatic episode in patients affected by recurrent urinary stones: A prospective study

Tommaso Cai¹, Daniele Tiscione¹, Marco Puglisi¹, Gianni Malossini¹, Lorenzo Ruggera², Paolo Verze³, Davide Arcaniolo⁴, Alessandro Palmieri⁵

¹ Department of Urology, Santa Chiara Regional Hospital, Trento, Italy;

² Department of Urology, University of Padua, Padua, Italy;

³ Department of Medicine, Surgery, Dentistry "Scuola Medica Salernitana" - University of Salerno, Baronissi, Italy;

⁴ Department of Urology, University Vanvitelli, Naples, Italy.

⁵ Department of Urology, University of Naples, Federico II, Naples, Italy.

Summary

Objective: The aim of this study is to evaluate the efficacy of a food supplement containing *Phyllanthus niruri* and *Chrysanthellum americanum* in association with potassium and magnesium citrates in the treatment and prophylaxis of urinary stones.

Materials and methods: Eighty-two patients (mean age 49.7 ± 11.2) with history of urinary stones received this food supplement, one capsule a day for 6 months. Each administration contained a combination of the following ingredients: 244 mg Potassium citrate, 735 mg Magnesium citrate, *Phyllanthus* (*Phyllanthus niruri*) herb d.e. 15% mg Tannins 220 mg, *Chrysanthellum* (*Chrysanthellum americanum* Vatke) plant d.e. $\frac{1}{4}$ 55 mg. After 6 months, all patients underwent urologic visit, urinalysis, imaging and quality of life (QoL) questionnaires evaluation. Each patient was also evaluated by computed tomography (CT) scan at baseline and at 6 months.

Result: From January 2018 to March 2019, 82 patients (mean age 49.7 ± 11.2) completed the follow-up period and were analyzed. Fifty patients showed lower stone dimensions (60.9%). The average stone size was 0.9 mm, with a significant reduction in comparison with the baseline ($-6.7 \text{ mm} \pm 3 \text{ mm}$) ($p < 0.001$). Forty-nine patients (59.7%) did not show any symptomatic episode with an improving in QoL ($+0.4 \pm 0.1$) ($p < 0.001$) in comparison with the baseline. At the end of the follow-up period, 27 patients out of 82 were stone-free (32.9%). Moreover, we report a significant reduction of patients with asymptomatic bacteriuria (ABU) between the baseline and the end of the follow-up evaluation ($p < 0.001$).

Conclusions: In conclusion, this food supplement is able to improve quality of life in patients with urinary stones, reducing symptomatic episodes and the prevalence of ABU.

KEY WORDS: Stones; *Phyllanthus niruri*; *Chrysanthellum americanum*; Potassium; Magnesium; Asymptomatic bacteriuria.

Submitted 16 April 2021; Accepted 26 April 2021

INTRODUCTION

Urinary tract stones are one of the most common cause of urological visits, with a prevalence among urological patients of 1-15% (1, 2). The impact on everyday clinical

practice is high, due to the high number of recurrences and due to the impact of symptoms on patients' quality of life (2, 3).

The recurrence rate of urinary calculi is 50% within 10 years of the first episode (3, 4). Symptomatic recurrence episodes are associated with high direct and indirect costs (admission to emergency departments, imaging, drugs and working day lost). For these reasons, the prevention of symptomatic episodes due to urinary stones should be the first aim in the management of this kind of patients. Several authors recommended some diet interventions for reducing the risk of urinary stone formation and its recurrence but there is no conclusive consensus in the literature regarding the effectiveness of dietary interventions and recommendations about specific diets for patients with urinary calculi (5). On the other hand, the use of medicinal plants and nutraceuticals have long been used worldwide for the management of recurrence in patients affected by urinary stones (6). Ettinger *et al.*, published in 1997 one of the first clinical trial on the use of potassium-magnesium citrate in preventing recurrent calcium oxalate kidney calculi, demonstrating that potassium-magnesium citrate effectively prevents recurrent calcium oxalate stones (7). Focusing on the plant extracts, *Phyllanthus niruri*, commonly known as "stone-breaker", is able to increase urinary excretion of magnesium and potassium and to cause a significant decrease in urinary oxalate and uric acid in patients with hyperoxaluria and hyperuricosuria, contributing to the elimination of urinary calculi (4). Moreover, *Chrysanthellum americanum* seems to be effective in the reduction of stone formation, probably due to the effect of chrysanthellin, a saponin, on the stone aggregation (8).

Starting from these evidences, we aim to evaluate the efficacy of a medical device containing *Phyllanthus niruri* and *Chrysanthellum americanum* in association with potassium and magnesium citrates in the treatment and prophylaxis of symptomatic episode in patients affected by recurrent uncomplicated urinary stones.

No conflict of interest declared.

MATERIALS AND METHODS

Study schedule and population

From January 2018 to March 2019, all patients attending two referral institutions with history of recurrent uncomplicated urinary stones were enrolled in this prospective phase IV, post-marketing clinical trial. All enrolled patients underwent a urological visit for inclusion and exclusion criteria assessment with *quality of life* (QoL) questionnaires, serum chemistry, urinalysis and non-contrast-enhanced CT scanner. All patients were encouraged to make lifestyle changes and received a food supplement containing *Phyllanthus niruri* and *Chrysanthellum americanum* in association with potassium and magnesium citrates, one capsule a day for 6 months. After 3 months, all patients were contacted by phone by the trialists in order to check the adherence to the treatment. After 6 months, all patients underwent urologic visit, urinalysis, imaging (CT scan) and QoL questionnaires evaluation. Figure 1 shows the study schedule.

Outcome measures

The main outcome measures were the reduction of symptomatic episodes and improvement in questionnaire result from baseline at the end of the follow-up period. Stone dimension reduction and stone-free status at 6 months follow-up CT scan were also considered as secondary outcome measures.

Inclusion and exclusion criteria

We considered for the inclusion, all patients with CT demonstration of one or multiple renal stones up to 15 mm. All patients with the following characteristics were excluded: serum creatinine level > 1.6 mg/dL, microbio-

logical demonstration of urinary tract infection, non-controlled diabetes, chronic liver disease and all the other serious comorbidities. Moreover, all patients with the evidence of ureterohydronephrosis or renal colic were excluded. Pregnant women were excluded, too.


Patients' clinical, laboratory and instrumental assessment

At the baseline, all patients underwent urological visit with QoL questionnaires, serum chemistry and blood analysis, urinalysis and non-contrast-enhanced CT scan. The identified calculi were classified according to their number, location (superior, middle, inferior calyx) and size. Clinical data comprised systolic and diastolic blood pressure and anthropometric evaluation (weight, height, *body mass index* (BMI)). Serum chemistry and blood analysis comprised blood count, assessment of urea, creatinine, sodium, potassium, glucose, uric acid, total and ionized calcium, total cholesterol and fractions, triglycerides, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, amylase and bilirubin levels. Urinalysis with urinary pH measurement and a urine culture were performed using spontaneous voided urine. Moreover, before enrolment all patients received a screening evaluation which includes a medical and dietary history by an experienced nephrologist. The enrolment has been done on the basis of the baseline metabolic profile, as suggested by the international guidelines (5).

Questionnaires

The impact of symptomatic episodes of renal stones on patients' QoL has been evaluated by using an Italian version of the Quality of Well-Being, a validated, multi-attribute health scale (9). This scale was selected because

Figure 1.



it has been successfully applied to acute illnesses, whereas other quality of life scales, including the *Short Form-36* (SF-36) Health Survey, are more suitable in chronic cases. Higher scores on the QoL scale reflect a higher quality of life (10).

Follow-up and efficacy assessment

After treatment, all patients were reassessed by urologic visit with questionnaire, serum chemistry, urine analysis and imaging, in order to evaluate the changes in number, location and size of the calculi at 3 and 6 months. At 3 months all patients underwent urinary tract sonography and at 6 months non-contrast-enhanced CT scanner.

At 3 months the stone evaluation was < performed by using urinary tract sonography in order to reduce the patients' exposition to X-ray. However, the stone free-rate has been calculated between the baseline and the 6 months follow-up CT scan.

Compounds characteristics

All patients were treated in line with the manufacturer's instructions (*Erbozeta S.p.A., RSM - https://www.erbozeta.com*). Each administration contained a combination of the following ingredients: 244 mg potassium citrate (93 mg potassium and 150 mg citrate), 735 mg magnesium citrate (30 mg magnesium and 160 mg citrate), *Phyllanthus* (*Phyllanthus niruri*) herb d.e. 15% mg Tannins 220 mg, *Chrysanthellum* (*Chrysanthellum americanum Vatke*) plant d.e. ¼ 55 mg.

Statistical analysis

As null hypothesis, we consider that there is no difference in terms of number of symptomatic episodes and QoL between baseline and the end of the follow-up evaluation. In order to obtain significant results to analyze, sample size calculation was based on the following assumptions: difference in terms of QoL between baseline and follow-up visit: $+ 0.3 \pm 0.06$; α error level, 0.05 two-sided; statistical power, 80%; anticipated effect size, Cohen's $d = 0.5$. The calculation yielded 72 individuals. Considering a drop-out rate of 10%, the final sample size was set to 79 patients. The statistical analysis was performed as follows: continuous variables are presented as median and *InterQuartile Range* (IQR) and categorical variables are presented as absolute (n) and relative (%) frequency distributions. t-test were used to compare average performance between enrolment and the follow-up evaluation, and between the periods before and after enrolment. The statistical analysis was performed using SPSS.

Ethical considerations

Due to the fact that this food supplement is already present in Italian pharmacopeia and that *Phyllanthus niruri* has been approved for the management of patients affected by urinary stones in Italy, the study did not require approval by the local ethics committee (IRB). Nevertheless, our study was conducted in line with Good Clinical Practice guidelines and the ethical principles laid down in the latest version of the Declaration of Helsinki. Before inclusion, all participants signed the written informed consent about personal data collection and storage, in accordance with national bylaws.

All anamnestic, clinical and laboratory data containing sensitive information about patients were de-identified in order to ensure analysis of anonymous data only. The de-identification process was performed by non-medical staff by means of dedicated software. A placebo run-in period was considered unnecessary.

RESULTS

From January 2018 to March 2019, 82 patients (mean age 49.7 ± 11.2) completed the follow-up period and were analyzed.

Baseline

At the baseline, the average stone size was 7.8 mm and 23 patients showed (ABU). The most common isolated strain was *Enterococcus faecalis* (18/23; 78.2%).

The median number of symptomatic episodes at baseline was 3 per year. The median number of calculi was 1 (range: 1-4). In 38 patients (46.3%) the calculi were located in the right kidney, 36 (43.9%) had left kidney lithiasis, while 8 patients had bilateral kidney lithiasis (9.8%). The mean stone diameter was 7.8 ± 1.1 mm.

The mean Hounsfield units was 637.1 ± 264.8 , in all enrolled patients. No difference, from the normal values, has been reported in terms of urine analysis parameters among the enrolled patients. The Table 1 shows all demographic and baseline clinical and instrumental characteristics of enrolled patients.

Table 1.

Patient clinical, instrumental and laboratory characteristics at the baseline.

No. of enrolled patients	82
Median age (\pm SD)	49.7 ± 11.2
Sex	
Male	49 (59.7)
Female	33 (40.3)
Body Mass Index (BMI) (\pm SD)	25.8 ± 6.3
Charlson Comorbidities Index	
0	75 (11.5)
1	7 (8.5)
2	-
Start of urinary lithiasis (years) (range)	2.3 ± 0.9
Number of symptomatic episodes per year (\pm SD)	3 ± 1.2
History of any endourological treatment (in the last 6 months)	
Yes	12 (14.6)
No	70 (85.4)
Median number of stones (range)	1 (1-4)
Mean stone size (\pm SD) (mm)	7.8 ± 1.1
Stones side	
Right kidney	38 (46.3)
Left kidney	36 (43.9)
Bilateral	8 (9.8)
Mean Hounsfield Units (\pm SD)	637.1 ± 264.8
Stones location (calyx)	
Superior	30 (36.5)
Middle	38 (46.4)
Inferior	14 (17.1)
Presence of asymptomatic bacteriuria	
Yes	23 (28.1)
No	59 (71.9)
Isolated strains	
Enterococcus faecalis	18 (78.1)
Escherichia coli	3 (13.3)
Klebsiella spp.	2 (8.6)

6 months follow-up

Adherence to the life-style changes and treatment

At the 3 months follow up by telephone call, 50 patients reported a high adherence to the life-style changes and to the treatment. At the end of the follow-up period, the adherence to the life-style changes and to the treatment was total in 60 patients (73.1%), while in twenty-two patients (26.8%) some minimal missing doses have been registered. A significant improvement has been reported between the 3- and 6-months evaluations in terms of adherence to the treatment and the life-style changes.

Clinical and instrumental outcomes and QoL

Twenty-seven patients out of 82 had no evidence of stone at the non-contrast-enhanced CT scanner (32.9%) at the end of the follow-up evaluation, reporting stone expulsion, while 50 patients showed lower stones dimension (60.9%).

The average stones size at the end of the follow-up was 0.9 mm (± 0.1 mm), with a significant reduction in comparison with the baseline (-6.7 mm ± 3 mm) ($p < 0.001$). Forty-nine patients (59.7%) did not show any symptomatic episode with an improving in QoL ($+0.4 \pm 0.1$) ($p < 0.001$) in comparison to the baseline. No difference, from the normal values, has been reported in terms of urine analysis parameters among the enrolled patients. The Table 2 shows all clinical and instrumental findings at the end of the follow-up.

Asymptomatic bacteriuria

At the end of follow-up evaluation, 3 patients reported ABU. A significant reduction of patients with ABU between the baseline and the end of the follow-up evaluation (23 vs 3; $p < 0.001$) has been reported.

A significant correlation between ABU reduction and stones number and dimension reduction has been reported ($r = 0.83$; $p < 0.001$).

Adverse effects

No mild or severe clinically significant adverse effects have been reported.

Table 2.

Clinical, instrumental and laboratory findings at each follow-up visit (3 and 6 months after treatment).

	Baseline	3 months	6 months
Adherence to life-style changes recommendations			
Patients with a high Grade of adherence	-	50 (60.9)	60 (73.1)
Clinical improvement			
Recurrence-free patients	0 (0%)	38 (46.3)	49 (59.7)
QoL	97.1	97.7	97.9
QoL improvement	-	$+0.3 \pm 0.2$	$+0.4 \pm 0.1$
Difference from baseline		$p < 0.001$	$p < 0.001$
Stone-free status	0 (0%)	19 (23.1)	23 (32.9)
Stone size (mm)			
Stone size (mm)	7.8 ± 1.1	3.1 ± 0.5	1.1 ± 0.5
Stone size reduction		-4.2 ± 2	-6.7 ± 3
Difference from baseline		$p < 0.001$	$p < 0.001$
Asymptomatic bacteriuria			
Patients with asymptomatic Bacteriuria	23	9 (10.9)	3 (3.6)
Difference from baseline		$p < 0.001$	$p < 0.001$

DISCUSSION

We demonstrated that a food supplement containing *Phyllanthus niruri* and *Chrysanthellum americanum* in association with potassium and magnesium citrates is able to improve QoL in patients with urinary stones, reducing symptomatic episodes, stones number and dimension and the prevalence of asymptomatic bacteriuria. Two important points should be discussed: The role of phytotherapy in the management of urinary stones and its mechanism of action and the relationship between urinary stones and ABU.

Role of phytotherapy in the management of urinary stones and mechanism of action

Phytotherapy is one of the first choices regarding pharmaceutical treatment of patients affected by urinary stones (2) due to the demonstrated efficacy (4, 11) and due to the patient's preference for phytotherapeutic compounds. Micali and Pucci, in two clinical trials, demonstrated that *Phyllanthus niruri* is able to reduce the stone size and improve the stone free status rate (4, 11). In line with these trials, we found a significant reduction in terms of stones size in comparison with the baseline (-6.7 mm ± 3 mm) ($p < 0.001$) and a high percentage of stone free patients after treatment.

These interesting findings are probably due to *Phyllanthus niruri* and *Chrysanthellum americanum* combination in association with potassium and magnesium citrates.

The efficacy of *Phyllanthus niruri* is probably augmented by the presence of *Chrysanthellum americanum*.

The role of *Chrysanthellum americanum* in the management of urinary stones is due to its interference, through the chrysantellin, a saponin, with some stages of crystallization in urine, such as a reduction in the nucleation, growth and aggregation of calcium oxalate crystals (8). Moreover, the synergistic effect of *Phyllanthus niruri* and *Chrysanthellum americanum* is probably due to its diuretic effects (12, 13). Furthermore, this food supplement contains potassium and magnesium citrates, although previous studies did not favor potassium citrate therapy. However, potassium can moderate the concentration of sodium in urine and promote the elevation of citrate, which acts to correct urinary pH and acidity, possibly contributing to an increase in calcium solubility and, then, interfere with some stages of crystallization in urine (14-17). This food supplement is, then, able to act into two different pathways: diuresis increasing and inhibition of nucleation, growth and aggregation of calcium oxalate crystals. Moving to the role of life-style changes, we found a significant improvement between the 3- and 6-months evaluations in terms of adherence to the treatment and life-style changes. The clinical reported efficacy in terms of reduction of symptomatic episodes, due to the treatment, drives the adherence to the life-style changes. In this sense, this food supplement should be considered, also, as an interesting tool for driving the adherence to the life-style changes and for obtaining a long-term efficacy on the stone recurrence. The high adherence to the treatment is due to the absence of reported adverse effects, too.

Relationship between urinary stones and asymptomatic bacteriuria

This was the first study that analyzed the efficacy of a

food supplement in reducing ABU in patients affected by urinary stones. ABU is a common clinical condition among recurrent stones patients, which does not generally require any treatment. However, the role of ABU in patients with recurrent urinary stones is not completely understood. Here, we demonstrated that this food supplement is able to statistically significantly reduce the prevalence of ABU among recurrent stone patients.

The efficacy on ABU is probably due to the increase of total daily diuresis and to the inhibition of nucleation, growth and aggregation of bacterial biofilm on the surface of calcium oxalate crystals. This mechanism is probably due to the *Phyllanthus niruri* and *Chrysanthellum americanum* action.

Finally, the role of bacteria biofilm on the urinary stone aggregation is another important field to deeply explore. Future studies are, however, needed to confirm these hypotheses.

CONCLUSIONS

In conclusion, this food supplement containing *Phyllanthus niruri* and *Chrysanthellum americanum* in association with potassium and magnesium citrates is able to reduce symptomatic episodes, improving QoL in patients with urinary stones and reduce the prevalence of ABU.

ACKNOWLEDGEMENTS

The authors thank all Medical and Nursing staff at the Department of Urology, Santa Chiara Regional Hospital for clinical assistance and support of this study.

REFERENCES

1. Khan SR, Pearle MS, Robertson WG, et al. Kidney stones. *Nat Rev Dis Primers*. 2016; 2:16008.
2. Cealan A, Coman RT, Simon V, et al. Evaluation of the efficacy of *Phyllanthus niruri* standardized extract combined with magnesium and vitamin B6 for the treatment of patients with uncomplicated nephrolithiasis. *Med Pharm Rep*. 2019; 92:153-157.
3. Curhan GC, Willett WC, Knight EL, Stampfer MJ. Dietary factors and the risk of incident kidney stones in younger women: Nurses' Health Study II. *Arch Intern Med*. 2004; 164:885-91.
4. Pucci ND, Marchini GS, Mazzucchi E, et al. Effect of *phyllanthus niruri* on metabolic parameters of patients with kidney stone: a perspective for disease prevention. *Int Braz J Urol*. 2018; 44:758-764.
5. Prezioso DI, Strazzullo P, Lotti T, et al. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group. *Arch Ital Urol Androl*. 2015; 87:105-20.
6. Cruces IL, Patelli THC, Tashima CM, Mello-Peixoto ECT. *Plantas medicinais no controle da urolitíase*. *Rev Bras Pl Med*. 2013; 15(4 Supl 1):780-8.
7. Ettinger B, Pak CY, Citron JT, et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. *J Urol*. 1997; 158:2069-73.
8. Becchi M, Bruneteau M, Trouilloud M, et al. Structure of a new saponin: chrysantellin A from *Chrysanthellum procumbens* Rich. *Eur J Biochem*. 1979; 102:11-20.

9. Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of wellbeing. *Health Serv. Res*. 1976; 11:478-507.

10. Apolone G, Mosconi P. The Italian SF-36 Health Survey: translation, validation and norming. *J Clin. Epidemiol*. 1998; 51:1025-36.

11. Micali S, Sighinolfi MC, Celia A, et al. Can *Phyllanthus niruri* affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. *J Urol*. 2006; 176:1020-1022.

12. Nishiura JL, Campos AH, Boim MA, et al. *Phyllanthus niruri* normalizes elevated urinary calcium levels in calcium stone forming (CSF) patients. *Urol Res*. 2004; 32:362-6.

13. Udupa AL, Sanjeeva, Benegal A, et al. Diuretic activity of *Phyllanthus niruri* (Linn) in rats. *J Health*. 2010; 2:511-2.

14. Lojanapiwat B, Tanthanuch M, Pripathanont C, et al. Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy. *Int Braz J Urol*. 2011; 37:611-616.

15. Soygür T, Akbay A, Küpeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. *J Endourol*. 2002; 16:149-152.

16. Cicerello E, Ciaccia M, Cova G, Mangano M. The impact of potassium citrate therapy in the natural course of Medullary Sponge Kidney with associated nephrolithiasis. *Arch Ital Urol Androl*. 2019; 91:.

17. Monti E, Trinchieri A, Magri V, et al. Herbal medicines for urinary stone treatment. A systematic review. *Arch Ital Urol Androl*. 2016; 88:38-46.

Correspondence

Tommaso Cai, MD (Corresponding Author)
ktommy@libero.it

Daniele Tiscione, MD

Marco Puglisi, MD

Gianni Malossini, MD

Department of Urology, Santa Chiara Hospital, Trento
Largo Medaglie d'Oro 9, Trento (Italy)

Lorenzo Ruggera, MD

Department of Urology, University of Padua, Padua, Italy.

Paolo Verze, MD

Department of Medicine, Surgery, Dentistry "Scuola Medica Salernitana" - University of Salerno, Baronissi, Italy

Alessandro Palmieri, MD

Department of Urology, University of Naples, Federico II, Naples (Italy)

Davide Arcaniolo, MD

Department of Urology, University Vanvitelli, Naples (Italy)

Article

Efficacy and Safety of Boldine Combined with *Phyllanthus niruri* and *Ononis spinosa* in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Single-Center, Retrospective Cohort Study

Ernesto Di Mauro ¹, Pietro Saldutto ², Roberto La Rocca ¹, Giuseppe Sangiorgi ³, Gianluigi Patelli ⁴, Biagio Barone ⁵, Vittore Verratti ⁶, Roberto Castellucci ⁷, Luigi Napolitano ^{1,*}, Fabrizio Iacono ⁸ and Vincenzo Maria Altieri ⁸

- ¹ Urology Unit, Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", 80138 Naples, Italy; ernestodm9@gmail.com (E.D.M.); robertolarocca87@gmail.com (R.L.R.)
- ² Department of Urology, Humanitas Gavazzeni, 24125 Bergamo, Italy; pietrosaldutto@gmail.com
- ³ Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy; gsangiorgi@gmail.com
- ⁴ Radiology Department, ASST Bergamo Est, 24068 Seriate, Italy; gianluigi.patelli@gmail.com
- ⁵ Department of Urology, Ospedale del Mare, ASL NA1 Centro, 80147 Naples, Italy; biagio.barone@unina.it
- ⁶ Department of Psychological, Health and Territorial Sciences, University "G. d'Annunzio" Chieti-Pescara, 66100 Chieti, Italy; vittore.verratti@unich.it
- ⁷ Department of Urology, SS. Annunziata Hospital, ASL 2 Abruzzo, 66100 Chieti, Italy; roberto.castellucci@gmail.com
- ⁸ Department of Medicine and Health Sciences "V. Tiberio", University of Molise, 86100 Campobasso, Italy; info@fabrizioiacono.it (F.I.); vincenzomaria.altieri@gmail.com (V.M.A.)
- * Correspondence: nluigi89@libero.it; Tel.: +39-0817462611



Citation: Di Mauro, E.; Saldutto, P.; La Rocca, R.; Sangiorgi, G.; Patelli, G.; Barone, B.; Verratti, V.; Castellucci, R.; Napolitano, L.; Iacono, F.; et al.

Efficacy and Safety of Boldine Combined with *Phyllanthus niruri* and *Ononis spinosa* in Medical Expulsive Therapy for Distal Ureteral Stones with Renal Colic: A Single-Center, Retrospective Cohort Study. *Medicina* **2024**, *60*, 1455. <https://doi.org/10.3390/medicina60091455>

Academic Editors: Joo Yong Lee and Davide Bolignano

Received: 22 July 2024

Revised: 26 August 2024

Accepted: 4 September 2024

Published: 5 September 2024



Copyright: © 2024 by the authors. Published by MDPI on behalf of the Lithuanian University of Health Sciences. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>)

Abstract: *Background and Objectives:* This study aimed to compare the effects and safety of boldine combined with *Phyllanthus niruri* and *Ononis spinosa* plus tamsulosin vs. tamsulosin alone in medical expulsive therapy (MET) for distal ureteral calculi. *Materials and Methods:* This retrospective cohort study was conducted on 159 renal colic patients with distal ureteric stones (≤ 10 mm). Patients aged between 18 and 70 years or older with distal ureteral (below the sacroiliac joint) stones ≤ 10 mm (defined by the largest diameter in three planes) confirmed by urinary ultrasonography and/or native computed tomography (CT). Patients were divided into two groups: A and B. Patients in Group A received tamsulosin 0.4 mg plus boldine combined with *Phyllanthus niruri* and *Ononis spinosa*, while those in Group B received tamsulosin 0.4 mg. The rate of stone expulsion, duration of stone expulsion, the dose and the duration of nonsteroidal anti-inflammatory drugs (NSAIDs), analgesic use, and adverse effects of drugs were recorded. *Results:* No differences were reported in demographic profiles between the two groups. The stone expulsion rate in Group A (84.8%) was higher in comparison to Group B (52.5%); the mean time of stone expulsion was 16.33 ± 4.75 days in Group A and 19.33 ± 6.42 days in Group B. The mean requirement time of analgesia was significantly less in Group A, 2.42 ± 2.56 , than in Group B, 6.25 ± 3.05 . Drug-related adverse effects (headache, dizziness, nausea, vomiting, postural hypotension, backache, and running nose) were comparable between the two groups. *Conclusions:* Tamsulosin plus boldine combined with *Phyllanthus niruri* and *Ononis spinosa* as medical expulsion therapy is more effective for distal ureteric stones with less need for analgesics and a shorter stone expulsion time than tamsulosin alone.

Keywords: kidney stone; boldine; MET; urolithiasis

1. Introduction

Urolithiasis is one of the most prevalent medical conditions worldwide, with a lifetime prevalence ranging from 1% to 15%. This condition affects millions of people across the world and presents a peak age of incidence typically occurring around 30 years [1]. Urolithiasis is not only widespread but also exhibits a significant gender disparity, affecting men two to three times more frequently than women. The formation of stones in the urinary tract is a complex process influenced by various factors, including diet, metabolism, infections, hereditary predispositions, congenital anatomical defects, environmental influences, and systemic disorders [2]. Among the different types of stones, ureteral stones are particularly common, accounting for approximately 20% of all cases of urolithiasis. Interestingly, about 70% of these ureteral stones are located in the distal third of the ureter, which is the portion closest to the bladder [3]. This specific location of the stones has significant implications for their treatment and potential for spontaneous passage. It is noteworthy that approximately 50% of ureteral stones eventually pass spontaneously without the need for surgical intervention. The likelihood of spontaneous passage is primarily determined by the size of the stone, with smaller stones being more likely to pass on their own [4]. The prevalence of urinary tract stones is higher in industrialized nations, which may be attributed to differences in diet, lifestyle, and environmental factors [5]. The composition of urine plays a crucial role in the formation of stones, with certain dietary habits and metabolic conditions increasing the risk of stone formation. The most common types of renal stones are composed of calcium oxalate, followed by calcium phosphate, uric acid, and struvite. Each type of stone has its unique characteristics and implications for treatment, making accurate identification essential for selecting the most appropriate therapeutic approach [6–8]. In recent years, significant advancements have been made in the treatment of ureteral stones, with both surgical and medical options available to patients [9]. One of the most established medical treatments for distal ureteral stones, particularly those less than 10 mm in size, is medical expulsive therapy (MET) [10]. The primary goal of MET is to facilitate the passage of stones, thereby avoiding the need for more invasive surgical procedures. This is achieved by using medications that relax the smooth muscles of the ureter, reduce peristaltic activity, and ultimately increase the rate of stone expulsion [11]. Among the various agents used in MET, alpha-1 adrenergic blockers, such as tamsulosin, are the most widely used. Tamsulosin works by relaxing the smooth muscles of the ureter, which helps to reduce the discomfort associated with stone passage and increases the likelihood of successful stone expulsion [12]. In addition to alpha-1 adrenergic blockers, newer classes of medications have also been introduced in the management of urolithiasis. Phosphodiesterase-5 (PDE5) inhibitors have been explored for their potential benefits in treating ureteral stones. These inhibitors regulate muscle contraction and relaxation through the metabolism of cyclic nucleotides, such as cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP). By influencing these pathways, PDE5 inhibitors may offer an additional mechanism for promoting stone passage [13]. In the last few decades, there has been a growing interest in the use of plant-derived bioactive compounds in the treatment of various diseases, including urolithiasis [14]. One of the most well-known plants in this regard is *Phyllanthus niruri* (PN), commonly referred to as the “stonebreaker”. PN has been used traditionally for its potential benefits in managing kidney stones, and recent studies have supported its role in interfering with different stages of stone formation [15]. PN appears to inhibit crystal aggregation, alter stone structure and composition, and promote ureteral relaxation. Additionally, it has been shown to reduce calcium excretion, which is a key factor in the formation of calcium-based stones [16]. Another plant-derived compound that has gained attention for its potential in treating urolithiasis is boldine. Boldine is known for its diverse biological effects, including antioxidant, anti-inflammatory, anti-epileptic, and neuroprotective properties. Recent research has also suggested that boldine may be effective in the treatment of urinary stones, particularly through its role in lithotripsy [17]. Furthermore, boldine has been reported to act as an alpha-1 adrenoceptor blocker, which may contribute to its effectiveness in promoting stone passage [18]. In light of these developments, a new

nutraceutical formulation has been developed, combining *Phyllanthus niruri*, *Ononis spinosa*, and boldine. This formulation aims to harness the synergistic effects of these plant-derived compounds in the management of distal ureteral stones. The present study was designed to evaluate the safety and efficacy of this novel nutraceutical combination, in conjunction with tamsulosin, as a medical expulsive therapy for distal ureteral stones. The study's findings have the potential to offer a new, effective treatment option for patients suffering from urolithiasis, particularly those with distal ureteral stones who wish to avoid more invasive interventions.

2. Materials and Methods

We conducted a retrospective cohort study at the tertiary care hospital, Humanitas Gavazzeni, in Bergamo, Italy, between March 2023 and December 2023. The study received approval from the Institutional Review Board of Humanitas Gavazzeni, Bergamo, Italy (protocol number 02/24 GAV). All procedures adhered to the ethical guidelines of the Helsinki Declaration, and all participants provided written informed consent prior to enrollment in the study. The inclusion criteria for the study were carefully defined to ensure the selection of appropriate participants. Eligible patients were adults over the age of 18 years who presented with distal ureteral stones, specifically located below the sacroiliac joint. The stones had to measure less than 10 mm in their largest diameter as confirmed by either urinary ultrasonography or non-contrast computed tomography (CT). Additional criteria included the submission to extracorporeal shock wave lithotripsy with a single residual ureteral stone fragment. Patients were excluded if they were currently using alpha-adrenoceptor antagonists, as these medications could interfere with the study's outcomes. Other exclusion criteria included the presence of a urinary tract infection, severe refractory pain, hydronephrosis, acute or chronic renal failure, multiple ureteral stones, bilateral ureteral calculi, or the presence of a single functioning kidney. Patients with any history of ureteral surgery or procedures, or urinary tract anomalies such as a horseshoe kidney or duplex urinary system, were also excluded. Furthermore, pregnant or lactating women, individuals with urethral stricture or a history of ureteral strictures, patients with diabetes mellitus, those with hypotension (defined as a systolic blood pressure below 100 mmHg), current users of corticosteroids, and anyone with known or suspected allergies to the study medications were not eligible to participate. A total of 186 patients who met the criteria were enrolled in the study. Patients were assigned to groups based on chronological criteria: those treated earlier in the study were assigned to Group A and received boldine combined with *Phyllanthus niruri* and *Ononis spinosa* plus one capsule of tamsulosin 0.4 mg daily; those treated later were assigned to Group B and received tamsulosin 0.4 mg alone daily, until spontaneous stone passage, up to a maximum of 28 days or the need for intervention (Figure 1). The patients were followed up for 28 days and then for a total follow-up of 3 months. At the screening visit, patients underwent clinical examination and the following data were collected: age, sex, stone side, and stone size. The stone expulsion time, analgesic use, number of hospital visits for pain, and adverse effects of drugs were noted. Patients were instructed to drink up to 2 L of water daily and to filter their urine with a thin cloth or net to detect stone expulsion. For pain control during colicky episodes, 50 mg sodium diclofenac suppositories were used on an as-needed basis.

2.1. Outcomes

The primary endpoint was the stone expulsion rate, defined as stone expulsion, confirmed by negative findings on an ultrasound scan or CT over the 28 d surveillance period. The secondary endpoints were the stone expulsion time, number of colicky attacks, analgesics required, and drug side effects. Patients who failed to pass the stone after 28 days were subjected to active treatment.




Figure 1. Flow chart of patients included in the study.

2.2. Statistical Analysis

Data were collected by filling in pro forma data sheets, which included the patients' demographic profiles, investigation reports, and the results of primary and secondary outcomes. Continuous data were expressed as means and standard deviations, while categorical data were expressed as frequencies and percentages. The normal distribution of data was assessed via the Kolmogorov–Smirnov test. Data were analyzed by using SPSS, ver. 17.0 (SPSS Inc., Chicago, IL, USA). Pearson's chi-squared test was utilized for categorical data, while an independent-samples Mann–Whitney U test was utilized for continuous variables. All statistical tests were based on two-tailed probability, and a p -value < 0.05 was considered statistically significant.

3. Results

Out of the 186 patients initially assessed for eligibility, 174 were deemed suitable for inclusion in the study. Fourteen patients were excluded due to not providing consent, and one patient refused to participate in the medical expulsive therapy (MET) involving boldine. Consequently, the final analysis included data from 159 patients, with 79 in the treatment group (Group A) and 80 in the control group (Group B).

The demographic characteristics of the study population were similar between the two groups. In Group A, the mean age of patients was 59.95 ± 17.16 years, while in Group B, the mean age was 56.03 ± 12.28 years. The overall gender distribution across both groups was nearly equal, with 49.7% of the patients being male and 50.3% female. Both groups were also comparable in terms of other baseline characteristics, including body mass index

(BMI), duration of symptoms, and stone parameters such as size and laterality (Table 1). The primary outcome of the study, the stone expulsion rate, showed a significant difference between the two groups. In Group A, which received the combination therapy of boldine, *Phyllanthus niruri*, *Ononis spinosa*, and tamsulosin, the stone expulsion rate was 84.8%. In contrast, Group B, which received tamsulosin alone, had a significantly lower expulsion rate of 52.5% ($p < 0.0001$). Additionally, the average time to stone expulsion was shorter in Group A, with a mean duration of 16.33 ± 4.75 days compared to 19.33 ± 6.42 days in Group B. Despite the overall success in stone expulsion, there were instances where the stones were not expelled within the initial treatment period. In Group B, 38 patients (47.5%) failed to expel the stones, compared to 12 patients (15.2%) in Group A. For these patients, the medical treatment was extended for an additional two weeks. Even with the extended treatment, a subset of patients still required surgical intervention due to the failure of medical management. Specifically, 10 patients in Group B (12.6%) and 4 patients in Group A (5%) ultimately underwent surgery. Another finding of the study was the requirement for analgesic use during the treatment period. Patients in Group A required significantly less analgesia, with a mean usage time of 2.42 ± 2.56 days, compared to 6.25 ± 3.05 days in Group B (Table 2). Regarding drug-related adverse effects, the incidence was relatively low and comparable between the two groups. Reported side effects included headache, dizziness, nausea, vomiting, postural hypotension, backache, and runny nose. Nausea was observed in two patients in Group A, while postural hypotension was reported in three patients in Group A and two in Group B. Overall, the side effects were manageable and did not significantly impact the patients' ability to continue the treatment.

Table 1. Demographic characteristics.

Group	Group A	Group B	p-Value
Age (Mean \pm SD)	59.95 \pm 17.169	56.03 \pm 12.286	0.069
BMI (Mean \pm SD)	26.81 \pm 3.71	26.18 \pm 3.67	0.217
Male/Female	47/32	32/48	0.071
Stone size, mm (Mean \pm SD)	7.49 \pm 2.46	6.79 \pm 2.49	0.109
Stone side, n% Right/Left	53%/47%	45%/55%	0.087
Serum creatinine, mg/dL	1.2 \pm 0.3	1.3 \pm 0.35	0.124

Table 2. Clinical outcomes of patients.

Group	Group A	Group B	p-Value
Number of colicky episode (Mean \pm SD)	1.01 \pm 0.67	2.40 \pm 1.22	<0.001
Pain score (1–10) (Mean \pm SD)	4.15 \pm 1.27	6.91 \pm 1.22	<0.001
Expulsion of stone time, days (Mean \pm SD)	16.33 \pm 4.75	19.33 \pm 6.42	<0.001
Doses of used NSAID mg (Mean \pm SD)	1242.11 \pm 938.45	2363.75 \pm 953.77	<0.001
Analgesic requirement time, days (Mean \pm SD)	2.42 \pm 2.56	6.25 \pm 3.05	<0.001

4. Discussion

To the best of our knowledge, this study is the first to assess the efficacy and safety of tamsulosin 0.4 mg combined with boldine, *Phyllanthus niruri*, and *Ononis spinosa* in the context of medical expulsive therapy (MET). In recent decades, various studies have investigated the efficacy of different drugs and natural herbal medicines in managing

urolithiasis, reflecting an ongoing interest in optimizing treatment strategies for stone expulsion. The European Association of Urology (EAU) guidelines highlight the benefits of MET in reducing the risk of intraoperative ureteral injury, accelerating the passage of stone fragments, and decreasing the frequency of colic episodes compared to surgical intervention guidelines reinforce the importance of exploring and validating non-invasive methods for managing ureteral stones [19]. Tamsulosin, an alpha-1 adrenergic receptor blocker, has been widely studied and is known to be effective in facilitating the passage of ureteral stones. Ibrahim et al. reported that tamsulosin was associated with a higher stone expulsion rate compared to alfuzosin, with rates of 85% and 75%, respectively. This underscores tamsulosin's role as a cornerstone in MET [20]. A meta-analysis by Cui et al., which included 56 randomized controlled trials (RCTs) and 9395 patients, further supported the efficacy of tamsulosin 0.4 mg. The analysis revealed that tamsulosin was associated with a higher stone expulsion rate (RR 1.44, 95% CI 1.35–1.55, $p < 0.01$), a shorter stone expulsion time (weighted mean difference -0.73 , 95% CI -1.00 to -0.45 , $p < 0.01$), and fewer instances of surgical intervention (RR 0.68, 95% CI 0.50–0.93, $p = 0.017$), particularly in stones larger than 5 mm [21]. More recently, PDE5i has been also explored in MET. PDE5i has shown direct effects on the relaxation of ureteral smooth muscle, influencing the frequency of peristaltic waves and overall muscle tone. A systematic review by Cardona et al., which included four studies and 580 patients, suggested that PDE5i could be an effective treatment in MET. However, the review emphasized the need for more high-quality trials to validate these findings [22]. Natural herbal medicines, known for their multi-component, multitarget, and multi-pathway effects, have also been studied for their potential in stone management. *Phyllanthus niruri* is one such herb that has shown promise in interfering with crucial stages of calculi formation, including crystal structure and composition [15]. *Phyllanthus niruri* contains triterpenes, which are considered an important anti-lithogenic factor [23]. These compounds reduce the urinary excretion of oxalate and calcium, while also interfering with glycosaminoglycans in the matrix of precipitating crystals, making the crystals smoother and more fragile. This property of *Phyllanthus niruri* suggests that it could play a significant role in the prevention of lithiasis, inhibiting calculus growth and facilitating the dispersion and easier elimination of crystals in urine [24]. In addition to its anti-lithogenic properties, *Phyllanthus niruri* has been reported to promote ureteral relaxation and reduce the excretion of promoters of urinary crystallization such as calcium. This is particularly beneficial following lithotripsy, where it can aid in clearing residual fragments. Micali et al. reported that self-administration of *Phyllanthus niruri* after extracorporeal shock wave lithotripsy significantly increased the stone-free rate, particularly for stones located in the lower calyces [25]. Furthermore, Pucci et al. demonstrated that supplementation with *Phyllanthus niruri* increased the magnesium/creatinine and potassium/creatinine ratios, both of which are protective against stone formation. Notably, *Phyllanthus niruri* is effective and well-tolerated, with few side effects reported [26]. Boldine, another plant-derived compound, has selective activity on alpha-1 adrenergic receptor subtypes and possesses renal vasodilatory properties. Boldine, an aporphine alkaloid derived from the leaves of *Peumus boldus*, offers a range of beneficial effects, including improved endothelial function, blood pressure regulation, antioxidant properties, cytoprotective abilities, and anti-inflammatory and antiproliferative characteristics. These properties suggest that boldine could be a valuable component of MET, particularly in its ability to reduce damage in kidney diseases and facilitate the passage of ureteral stones [27]. Ureteral peristalsis and ureteral smooth muscle relaxation represent an important issue in MET. Ureteral peristalsis is regulated by interstitial cells of Cajal (ICC)-like cells, which represent the renal pacemaker cells [28]. Recently, the literature has shown the expression of different receptors along the ureter, particularly in the distal one-third of ureter, with different pharmacology effects [29]. In particular, α_{1A} -adrenoceptor subtypes seem to be involved in contractile responses [30]. In fact, the inhibition of these receptors reduces the ureteral basal tone and increases the intra-luminal ureteral pressure. *P. niruri* showed an important activity in ureteral motility: Calixto et al. reported that alkaloids extracted from *P. niruri* present an antispasmodic

activity, due to smooth muscle relaxation [31]. In fact, they reported that an alkaloid called ALK-1 was able to induce smooth muscle relaxation. Recently, Maisto et al. reported the myorelaxant effects of a nutraceutical formulation containing PN on human pulmonary artery smooth muscle cells (HPASMCs). The NF induced a decreased muscle contractility of -49.4% ($p < 0.01$) compared to the control [14]. According to Ivorra et al., boldine has procynetic and diuretic effects on kidneys and ureters and stimulates peristalsis of the urinary musculature [32]. The muscle relaxation increases the chance of stone passage and reduces the time to expulsion.

Ononis spinosa is a flowering shrub native to the Mediterranean, Asia, and Africa, traditionally used for various health problems, including kidney and bladder diseases. It has demonstrated antibiotic, antifungal, antipyretic, anti-inflammatory, antiseptic, and diuretic effects. Historically, it has been widely used in the treatment of rheumatism, urinary tract infections, and skin diseases [33]. Bashan et al. reported that *Ononis spinosa* exhibits a direct litholytic effect on kidney stones, particularly those composed of uric acid. Additionally, Addotey et al. found that a dichloromethane extract from *Ononis spinosa* has anti-hyaluronidase activity, which increases diuresis and could contribute to stone expulsion [34,35]. In the present study, the stone expulsion rate was significantly higher in the group receiving the combination therapy (84.8% vs. 52.5%) compared to the group receiving tamsulosin alone. The three herbal extracts—boldine, *Phyllanthus niruri*, and *Ononis spinosa*—appear to work synergistically to stimulate ureteral contractions and peristalsis, reduce the adhesivity of crystalloids, and promote stone expulsion. These multifactorial activities suggest that such nutraceutical products can interact with different stages of stone formation and expulsion, offering an alternative or complementary treatment to traditional pharmacotherapies for urolithiasis. This approach could potentially reduce treatment costs and minimize side effects associated with conventional therapies. While this study is pioneering in assessing the efficacy and safety of combining boldine, *Phyllanthus niruri*, and *Ononis spinosa* with tamsulosin in MET for distal ureteral calculi, it is important to acknowledge the study's limitations. First, the retrospective and single-center nature of the study may introduce biases related to patient selection and treatment outcomes. Second, the relatively small sample size limits the statistical power of the findings and may affect the generalizability of the results. Third, the extensive exclusion criteria, although necessary for ensuring a homogeneous study population, may limit the applicability of the findings to the broader population of patients with ureteral stones. To address these limitations and build on the promising results of this study, further research is needed. Future studies should aim to conduct randomized, prospective, double-blind, placebo-controlled trials with larger sample sizes. Such trials would provide stronger evidence to support the use of this combination therapy in clinical practice. Additionally, exploring the mechanisms of action of these herbal extracts in greater detail could offer insights into how they can be optimized for use in MET and other therapeutic applications.

5. Conclusions

This study provides valuable preliminary evidence that combining boldine, *Phyllanthus niruri*, and *Ononis spinosa* with tamsulosin may serve as an effective and safe alternative to conventional MET for treating distal ureteral calculi. The multifaceted effects of these herbal compounds, particularly in promoting ureteral relaxation and facilitating stone expulsion, highlight their potential significance in the future management of urolithiasis. However, confirming these findings through further research is essential.

Author Contributions: Conceptualization, E.D.M., L.N. and V.M.A.; methodology, F.I., P.S. and G.P.; validation, B.B. and G.P.; formal analysis, B.B.; data curation, R.L.R. and G.S.; writing—original draft preparation, E.D.M., L.N., V.V. and V.M.A.; writing—review and editing, R.C.; visualization and supervision, F.I. and V.V. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: This study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Humanitas Gavazzeni, Bergamo, Italy (protocol code 02/24 GAV-23/01/2024, approval date 23 January 2024).

Informed Consent Statement: Informed consent was obtained from all subjects involved in this study.

Data Availability Statement: The data presented in this study are available upon request from the corresponding author. The data are not publicly available due to privacy restrictions.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- Zhang, L.; Zhang, X.; Pu, Y.; Zhang, Y.; Fan, J. Global, Regional, and National Burden of Urolithiasis from 1990 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. *Clin Epidemiol.* **2022**, *15*, 971–983. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Xu, J.Z.; Li, C.; Xia, Q.D.; Lu, J.L.; Wan, Z.C.; Hu, L.; Lv, Y.M.; Lei, X.M.; Guan, W.; Xun, Y.; et al. Sex disparities and the risk of urolithiasis: A large cross-sectional study. *Ann. Med.* **2022**, *54*, 1627–1635. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Yuksel, M.; Yilmaz, S.; Tokgoz, H.; Yalcinkaya, S.; Baş, S.; Ipekci, T.; Yildiz, A.; Ates, N.; Savas, M. Efficacy of silodosin in the treatment of distal ureteral stones 4 to 10 mm in diameter. *Int. J. Clin. Exp. Med.* **2015**, *8*, 19086–19092. [[PubMed](#)] [[PubMed Central](#)]
- Miller, O.F.; Kane, C.J. Time to stone passage for observed ureteral calculi: A guide for patient education. *J. Urol.* **1999**, *162*, 688–690. [[CrossRef](#)] [[PubMed](#)]
- Wu, Y.C.; Hou, C.P.; Weng, S.C. Lifestyle and Diet as Risk Factors for Urinary Stone Formation: A Study in a Taiwanese Population. *Medicina* **2023**, *59*, 1895. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Ferraro, P.M.; Bargagli, M.; Trinchieri, A.; Gambaro, G. Risk of Kidney Stones: Influence of Dietary Factors, Dietary Patterns, and Vegetarian-Vegan Diets. *Nutrients* **2020**, *12*, 779. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Khalili, P.; Jamali, Z.; Sadeghi, T.; Esmaeili-Nadimi, A.; Mohamadi, M.; Moghadam-Ahmadi, A.; Ayoobi, F.; Nazari, A. Risk factors of kidney stone disease: A cross-sectional study in the southeast of Iran. *BMC Urol.* **2021**, *21*, 141. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Cirillo, L.; Manfredi, C.; Barone, B.; Morgera, V.; Cacace, G.; Mastrangelo, F.; Di Bello, F.; Abate, M.; Arcaniolo, D.; Spirito, L.; et al. Mobile health applications in kidney stone disease management: A reliable support for patients? *Arch. Ital. Urol. Androl.* **2023**, *95*, 11076. [[CrossRef](#)] [[PubMed](#)]
- Bhanot, R.; Jones, P.; Somani, B. Minimally Invasive Surgery for the Treatment of Ureteric Stones-State-of-the-Art Review. *Res. Rep. Urol.* **2021**, *13*, 227–236. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Belkovsky, M.; Zogaib, G.V.; Passerotti, C.C.; Artifon, E.L.A.; Otoch, J.P.; da Cruz, J.A.S. Tamsulosin vs. Tadalafil as medical expulsive therapy for distal ureteral stones: A systematic review and meta-analysis. *Int. Braz. J. Urol.* **2023**, *49*, 668–676. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Khereddine, M.; Tiéoulé, T.; Aziz, K.; Kays, C.; Rhouma, B.; Ahmed, S.; Yassine, N. Medical Expulsive Therapy (MET) for Large Distal Ureteral Stones: A Prospective Study Comparing Three Drugs. *Open J. Urol.* **2020**, *10*, 152–157. [[CrossRef](#)]
- Lipkin, M.; Shah, O. The use of alpha-blockers for the treatment of nephrolithiasis. *Rev. Urol.* **2006**, *8* (Suppl. S4), S35–S42. [[PubMed](#)]
- Mirone, V.; Napolitano, L.; D’Emmanuele di Villa Bianca, R.; Mitidieri, E.; Sorrentino, R.; Vanelli, A.; Vanacore, D.; Turnaturi, C.; La Rocca, R.; Celentano, G.; et al. A new original nutraceutical formulation ameliorates the effect of Tadalafil on clinical score and cGMP accumulation. *Arch. Ital. Urol. Androl.* **2021**, *93*, 221–226. [[CrossRef](#)] [[PubMed](#)]
- Maisto, M.; Schiano, E.; Luccheo, G.; Luccheo, L.; Alfieri, E.; Piccolo, V.; Iannuzzo, F.; Di Lorenzo, R.; Tenore, G.C. Efficacy of a Multicomponent Nutraceutical Formulation for the Prevention and Treatment of Urinary Tract Stones. *Int. J. Mol. Sci.* **2023**, *24*, 8316. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Boim, M.A.; Heilberg, I.P.; Schor, N. Phyllanthus niruri as a promising alternative treatment for nephrolithiasis. *Int. Braz. J. Urol.* **2010**, *36*, 657–664. [[CrossRef](#)] [[PubMed](#)]
- Nuss, G.R.; Rackley, J.D.; Assimos, D.G. Adjunctive therapy to promote stone passage. *Rev. Urol.* **2005**, *7*, 67–74. [[PubMed](#)] [[PubMed Central](#)]
- Lamba, D.; Dwivedi, D.K.; Yadav, M.; Kumar YR, S. Boldine: A narrative review of the bioactive compound with versatile biological and pharmacological potential. *J. Complement. Integr. Med.* **2024**, *6*, 7. [[CrossRef](#)] [[PubMed](#)]
- Chuliá, S.; Moreau, J.; Naline, E.; Noguera, M.A.; Ivorra, M.D.; D’Ocón, M.P.; Advenier, C. The effect of S-(+)-boldine on the alpha 1-adrenoceptor of the guinea-pig aorta. *Br. J. Pharmacol.* **1996**, *119*, 1305–1312. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
- Şener, T.E.; Taily, T.; Tanidir, Y.; Keller, E.X.; Pietropaolo, A.; Rivas, J.G.; Hameed, Z.; DEConinck, V.; Tefik, T.; Sarica, K.; et al. Urologists’ opinion on treating asymptomatic stones: Would we treat ourselves as we treat our patients? Survey from European Association of Urology, Young Academic Urologists, Endourology and Urolithiasis working party. *Turk. J. Med. Sci.* **2023**, *7*, 185–193. [[CrossRef](#)] [[PubMed](#)]
- Ibrahim, A.K.; Mahmood, I.H.; Mahmood, N.S. Efficacy and safety of tamsulosin vs. alfuzosin as medical expulsive therapy for ureteric stones. *Arab. J. Urol.* **2013**, *11*, 142–147. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

21. Cui, Y.; Chen, J.; Zeng, F.; Liu, P.; Hu, J.; Li, H.; Li, C.; Cheng, X.; Chen, M.; Li, Y.; et al. Tamsulosin as a Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J. Urol.* **2019**, *201*, 950–955. [[CrossRef](#)] [[PubMed](#)]
22. Montes Cardona, C.E.; García-Perdomo, H.A. Efficacy of phosphodiesterase type 5 inhibitors for the treatment of distal ureteral calculi: A systematic review and meta-analysis. *Investig. Clin. Urol.* **2017**, *58*, 82–89. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
23. Cealan, A.; Coman, R.T.; Simon, V.; Andras, I.; Telecan, T.; Coman, I.; Crisan, N. Evaluation of the efficacy of *Phyllanthus niruri* standardized extract combined with magnesium and vitamin B6 for the treatment of patients with uncomplicated nephrolithiasis. *Med. Pharm. Rep.* **2019**, *92*, 153–157. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
24. Freitas, A.M.; Schor, N.; Boim, M.A. The effect of *Phyllanthus niruri* on urinary inhibitors of calcium oxalate crystallization and other factors associated with renal stone formation. *BJU Int.* **2002**, *89*, 829–834. [[CrossRef](#)] [[PubMed](#)]
25. Micali, S.; Sighinolfi, M.C.; Celia, A.; De Stefani, S.; Grande, M.; Cicero, A.F.; Bianchi, G. Can *Phyllanthus niruri* affect the efficacy of extracorporeal shock wave lithotripsy for renal stones? A randomized, prospective, long-term study. *J. Urol.* **2006**, *176*, 1020–1022. [[CrossRef](#)] [[PubMed](#)]
26. Pucci, N.D.; Marchini, G.S.; Mazzucchi, E.; Reis, S.T.; Srougi, M.; Evazian, D.; Nahas, W.C. Effect of *phyllanthus niruri* on metabolic parameters of patients with kidney stone: A perspective for disease prevention. *Int. Braz. J. Urol.* **2018**, *44*, 758–764. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
27. de Souza, P.; da Silva, R.C.V.; da Silva, L.M.; Steimbach, V.M.B.; Moreno, K.G.T.; Gasparotto Junior, A. Boldine, an Alkaloid from *Peumus boldus* Molina, Induces Endothelium-Dependent Vasodilation in the Perfused Rat Kidney: Involvement of Nitric Oxide and Small-Conductance Ca²⁺-Activated K⁺ Channel. *Evid. Based Complement. Altern. Med.* **2022**, *2022*, 4560607. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
28. Lee, H.W.; Baak, C.H.; Lee, M.Y.; Kim, Y.C. Spontaneous contractions augmented by cholinergic and adrenergic systems in the human ureter. *Korean J. Physiol Pharmacol.* **2011**, *15*, 37–41. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]
29. Lim, I.; Sellers, D.J.; Chess-Williams, R. Current and emerging pharmacological targets for medical expulsive therapy. *Basic Clin. Pharmacol. Toxicol.* **2022**, *130* (Suppl. S1), 16–22. [[CrossRef](#)] [[PubMed](#)]
30. Sasaki, S.; Tomiyama, Y.; Kobayashi, S.; Kojima, Y.; Kubota, Y.; Kohri, K. Characterization of α 1-adrenoceptor subtypes mediating contraction in human isolated ureters. *Urology* **2011**, *77*, 762.e13–762.e17. [[CrossRef](#)] [[PubMed](#)]
31. Calixto, J.B.; Santos, A.R.; Cechinel Filho, V.; Yunes, R.A. A review of the plants of the genus *Phyllanthus*: Their chemistry, pharmacology, and therapeutic potential. *Med. Res. Rev.* **1998**, *18*, 225–258. [[CrossRef](#)] [[PubMed](#)]
32. Martinez, S.; Madrero, Y.; Elorriaga, M.; Noguera, M.A.; Cassels, B.; Sobarzo, E.; D’Ocon, P.; Ivorra, M.D. Halogenated derivatives of boldine with high selectivity for α 1A-adrenoceptors in rat cerebral cortex. *Life Sci.* **1999**, *64*, 1205–1214. [[CrossRef](#)] [[PubMed](#)]
33. Bashan, I.; Bozlu, M. The possible litholytic effect of *Ononis spinosa* L. on various human kidney stones—An in vitro experimental evaluation. *J. Herb. Med.* **2020**, *22*, 100345. [[CrossRef](#)]
34. Addotey, J.N.; Lengers, I.; Jose, J.; Gampe, N.; Béni, S.; Peterreit, F.; Hensel, A. Isoflavonoids with inhibiting effects on human hyaluronidase-1 and norneolignan clitorienolactone B from *Ononis spinosa* L. root extract. *Fitoterapia* **2018**, *130*, 169–174. [[CrossRef](#)] [[PubMed](#)]
35. Spiegler, V.; Gierlikowska, B.; Saenger, T.; Addotey, J.N.; Sendker, J.; Jose, J.; Kiss, A.K.; Hensel, A. Root Extracts From *Ononis spinosa* Inhibit IL-8 Release via Interactions With Toll-Like Receptor 4 and Lipopolysaccharide. *Front. Pharmacol.* **2020**, *11*, 889. [[CrossRef](#)] [[PubMed](#)] [[PubMed Central](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.